News stories about Marinus Pharmaceuticals (NASDAQ:MRNS) have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 48.1012091558021 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of MRNS traded up $0.05 during trading hours on Friday, hitting $4.62. 5,725 shares of the stock were exchanged, compared to its average volume of 955,157. Marinus Pharmaceuticals has a 12-month low of $4.73 and a 12-month high of $4.75.
Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.01.
MRNS has been the subject of a number of recent analyst reports. HC Wainwright initiated coverage on Marinus Pharmaceuticals in a research report on Thursday, February 15th. They issued a “buy” rating and a $33.00 price objective for the company. Mizuho started coverage on Marinus Pharmaceuticals in a research report on Monday, March 19th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, ValuEngine upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $18.75.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.